Adam Levin, MD, joined the Johns Hopkins Department of Orthopaedic Surgery as an assistant professor in orthopaedic oncology. Dr. Levin comes to Johns Hopkins after working as an orthopaedic oncologist at the North Shore/LIJ Health System in New York. He completed his residency in orthopaedic surgery at Long Island Jewish Medical Center, and a fellowship in orthopaedic oncology at the Memorial Sloan-Kettering Cancer Center. Dr. Levin offers care and consultations for adults and children with bone and soft tissue tumors of the pelvis and extremities. He has extensive experience in performing limb-sparing and complex extremity reconstruction surgeries. Dr. Levin has a special interest in surgical palliation and biologic reconstruction. Dr. Levin is a member of the American Academy of Orthopaedic Surgeons and the Musculoskeletal Tumor Society. Dr. Levin is rated as an Elite provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Ollier Disease, Hip Replacement, and Osteotomy.

Dr. Christine Pratilas is a pediatric medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and Associate Professor of Oncology, Pediatrics & Cellular and Molecular Medicine at the Johns Hopkins University School of Medicine. She joined the Hopkins pediatric sarcoma team in 2014. Dr. Pratilas received her undergraduate degree in Biology from Drew University in New Jersey and her medical degree from UMDNJ - Robert Wood Johnson Medical School (now Rutgers University), where she also completed her internship and residency from 1999 to 2002. From 2002 to 2005 she was a fellow in hematology and oncology in the Memorial Sloan Kettering Cancer Center (MSKCC) Department of Pediatrics, and in the Department of Pediatric Hematology and Oncology at New York Weill Cornell Medical Center. She was a postdoctoral research fellow in Dr. Neal Rosen’s Molecular Oncogenesis Laboratory at MSKCC. From 2006 to 2014 she was attending in Pediatric Oncology at MSKCC, specializing in developmental therapeutics & sarcoma. She has been the director of the pediatric sarcoma program at Hopkins since 2018. Dr. Pratilas focuses her research on cancer-associated pathways and signal transduction, which involves figuring out how a cell’s internal molecular pathways work, and how those pathways can be molecularly controlled. This knowledge is the basis for developing promising new molecularly targeted cancer therapies, which is the focus of Dr. Pratilas’s research. Among her important scientific contributions is advancing our understanding of how certain proteins that can be mutated in cancer, known as RAF kinases (specifically BRAF), affect a cancer cell’s behavior. The research in Dr. Pratilas' laboratory is focused on RAS signal transduction pathways, concentrating on pediatric sarcomas such as rhabdomyosarcoma and malignant peripheral nerve sheath tumors, in order to develop novel therapeutics for children with these tumors. Dr. Pratilas is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Adult Soft Tissue Sarcoma, and Osteotomy.

Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Ganglioneuroblastoma.

Brock Lindsey, M.D., is an orthopaedic surgeon specializing in orthopaedic oncology. He treats children and adults with all types of bone and soft tissue sarcomas. Dr. Lindsey has expertise in nanoparticle delivery of immunotherapy, immunodiagnostics as a novel treatment for osteosarcoma, as well as complex reconstruction after amputation, including osseointegration. Dr. Lindsey earned his medical degree from the University of Cincinnati. He then completed an orthopaedic surgery residency at West Virginia University’s (WVU) J.W. Ruby Memorial Hospital, becoming the department’s first to complete a research fellowship during residency. Dr. Lindsey also pursued a fellowship in musculoskeletal oncology at the University of Pittsburgh Medical Center (UPMC) and UPMC Children’s Hospital before returning to WVU Medicine as an attending physician. During his 12 years at WVU Medicine, Dr. Lindsey created programs in musculoskeletal oncology and adult reconstruction as well as a multidisciplinary amputation clinic. He also led a musculoskeletal research laboratory into the national rankings for federal funding for orthopaedic surgery departments. His research focuses on improving treatment strategies for metastatic osteosarcoma and exploring human/machine interfaces for amputees. His work has been published in local, national and international basic science and clinical research journals. Dr. Lindsey has experience mentoring and training students at all levels from undergraduate and graduate students to postdoctoral positions. He won Press Ganey’s “Top Provider” award every year between 2013 and 2018. He also founded ICaPath, a biotech startup derived from his laboratory research that is currently working toward a first in-human clinical trial. Videos Brock Lindsey, M.D.Orthopaedic Oncologist OsseointegrationQ&A with Dr. Brock Lindsey. Dr. Lindsey is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Bone Tumor, Adult Soft Tissue Sarcoma, Osteosarcoma, Hip Replacement, and Knee Replacement.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

Akila Viswanathan, M.D., M.P.H., is the director for the Department of Radiation Oncology and Molecular Radiation Sciences, and a professor of radiation oncology, gynecology/obstetrics and oncology for Johns Hopkins University School of Medicine. Dr. Viswanathan leads the department emphasizing excellence in clinical care, research and education. She has expertise with gynecologic cancers and their treatment, including cervical and uterine cancers and image-guided brachytherapy. She has developed numerous clinical innovations and initiated several system-wide integration efforts at all sites, including Green Spring Station, Bayview, Johns Hopkins Hospital, Suburban's Rockledge site, and Sibley Memorial Hospital for the Johns Hopkins Department of Radiation Oncology. Dr. Viswanathan earned her undergraduate degree at Harvard University, her medical degree at the University of Pittsburgh School of Medicine, followed by her Masters in Public Health and Masters in Epidemiology at the Harvard School of Public Health. She completed a residency in radiation oncology at the Joint Center for Radiation Therapy at Harvard Medical School, where she served as chief resident. She has had research grant funding through the National Cancer Institute K07, R21 and R01 programs to support efforts in gynecologic cancers, specifically looking at the identification of gynecologic tumors at the time of brachytherapy under magnetic resonance imaging. The research team has developed several novel clinical innovations. Dr. Viswanathan has been named one of America's Top Doctors by Newsweek, Who’s who in America, and a Super Doctor by the Washington Post magazine. Dr. Viswanathan served as President and Chair of the Board of the American Brachytherapy Society; Chair of Education Committee for American Society for Radiation Oncology; and, on the Gynecologic Cancer Steering Committee and the uterine cancer task force for the National Cancer Institute. Dr. Akila Viswanathan has published more than 200 articles and chapters, and lectures nationally and internationally. She is the Editor-in-Chief for Seminars in Radiation Oncology. She is on the editorial board of Gynecologic Oncology and Brachytherapy, and is an editor of several textbooks including Gynecologic Radiation Therapy: Novel Approaches to Image-Guidance and Management, Radiation Therapy Techniques for Gynecologic Cancers, and Gunderson and Tepper's Clinical Radiation Oncology. Make A Gift. Dr. Viswanathan is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. Her top areas of expertise are Vaginal Cancer, Cervical Cancer, Vulvar Cancer, Vulvectomy, and Cordotomy.

William Regine is a Radiation Oncologist in Baltimore, Maryland. Dr. Regine is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Pancreatic Cancer, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Anal Cancer.

Dr. Amanda Nickles Fader is a professor in the Johns Hopkins Hospital Department of Gynecology and Obstetrics and the Sidney Kimmel Cancer Center. She is the former fellowship director and division director of the Johns Hopkins Kelly Gynecologic Oncology Service and currently is Vice Chair of Gynecologic Surgical Operations and the Director of the Center for Rare Gynecologic Cancers. Additionally, she serves as the 2024-2025 President of the Society of Gynecologic Oncology. Dr. Fader received her undergraduate degree with highest distinction in music (violin performance) and pre-medicine from the University of Virginia. She earned her medical degree from the Medical College of Virginia, and completed her residency in obstetrics and gynecology at the Magee-Women’s Hospital of UPMC in Pittsburgh. Dr. Fader then underwent gynecologic oncology fellowship training at the Cleveland Clinic. She has co-authored more than 230 publications in peer-reviewed medical journals and is recognized as an expert in rare gynecologic tumors, clinical trials and quality and safety in surgery. She has a special interest in uterine serous carcinoma and low-grade serous carcinoma of the ovary and currently serves as the PI or co-PI of three international NRG Oncology clinical trials. Dr. Fader serves as a national board examiner in gynecologic oncology for the American Board of Obstetrics and Gynecology and Associate Editor of the Gynecologic Oncology journal is a member of the Rare Tumor and Uterine Corpus Committees of the NRG/Gynecologic Oncology Group. She is also co-founder of the Society of Gynecologic Oncology BRIDGES Program, a two-year longitudinal clinical trials and career development program for early-career oncologists. She has been the recipient of several research grants and awards for her research, including the Society of Gynecologic Oncology Innovations Award, the Best AAGL Paper in Minimally Invasive Gynecologic Oncology Surgery, a Department of Defense Ovarian Cancer Clinical Trials Academy Leadership Award, and National Cancer Institute Cervical SPORE grant. Dr. Fader is consistently recognized for clinical excellence on lists such as Baltimore magazine’s Top Docs and Castle Connolly’s Top Doctors, and is a recipient of the Top 10 Docs, Compassionate Doctors and Patient Choice Awards from Vitals.com. She has particular expertise with the surgical and medical management of uterine (endometrial), ovarian, cervical and vulvar cancers, as well as the treatment of women who are at high risk for developing a gynecologic malignancy. She has a special interest in caring for patients throughout the entire spectrum of their lives: from preventive oncology — minimizing key risk factors that can lead to gynecologic cancers — to survivorship initiatives addressing all aspects of recovery, including emotional well-being, sexual health and clinical follow-up. Dr. Fader is rated as an Experienced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ovarian Cancer, Bladder Reconstruction, and Hernia Surgery.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Experienced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Dr. Armstrong works primarily in the area of women's malignancies, with a particular emphasis on breast cancer, ovarian cancer and other gynecologic malignancies, and the genetics of breast and ovarian cancer. She directs the medical gynecologic oncology clinical service and oversees therapeutic clinical trials in gynecologic cancers. Dr. Armstrong's clinical focus is on the development of new therapeutic approaches to the treatment of breast cancer and gynecologic malignancies. Particular areas of interest are intraperitoneal therapy in ovarian cancer and targeted biologic therapies. Dr. Armstrong also directs the Kimmel Cancer Center's Breast and Ovarian Cancer Screening Service, a genetic counseling service that focuses on identifying patients at risk for cancer and examination of new strategies for cancer screening and prevention. Dr. Armstrong has lectured locally, nationally and internationally. She is active in the Gynecologic Oncology Group, serving on the Medical Oncology, Developmental Therapeutics and Phase I GOG committees and as chair of several clinical trials through this group. She is a representative of the Southwest Oncology Group to the Gynecologic Cancer Steering Committee of the National Cancer Institute. Dr. Armstrong also serves as a representative of Johns Hopkins to the National Cooperative Cancer Network serving on the ovarian cancer and breast cancer risk reduction panels. She has participated as a member of the Cancer Working Group for the Office of Research on Women's Health for the National Institutes of Health, as a scientific reviewer for the breast and ovarian cancer research programs of the Department of Defense and the National Cancer Institute, as a reviewer for the NCI Special Emphasis Panel for Insight Awards to Stamp Out Breast Cancer and as a member of the NCI SPORE Program parent committee. Dr. Armstrong also is co-principal investigator for the NCI National Clinical Trials Network (NCTN) Lead Academic Participating Site (LAPS) at Johns Hopkins, now the major avenue for adult oncology clinical trials in the country. Recent work includes immune checkpoint inhibitor therapy in endometrial cancers with microsatellite instability and PARP inhibition in ovarian cancer. Dr. Armstrong is rated as an Experienced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Testicular Yolk Sac Tumor, and Ovarian Cancer.

Elizabeth Nichols is a Radiation Oncologist in Baltimore, Maryland. Dr. Nichols is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. Her top areas of expertise are Breast Cancer, Angiosarcoma, Cervical Cancer, and Adult Soft Tissue Sarcoma.

Jason Molitoris is a Radiologist and a Radiation Oncologist in Baltimore, Maryland. Dr. Molitoris is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Prostate Cancer, Adult Soft Tissue Sarcoma, Familial Prostate Cancer, Anal Cancer, and Gastrostomy.

Maitri Kalra is a Hematologist Oncology specialist and an Oncologist in Lutherville, Maryland. Dr. Kalra has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as an Advanced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

Debashish Bose is a Surgical Oncologist and a General Surgeon in Baltimore, Maryland. Dr. Bose is rated as an Experienced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Pancreatic Pseudocyst, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Bose is currently accepting new patients.

Daniel Rhee, M.D., M.P.H., joins the Johns Hopkins Department of Surgery as Assistant Professor of Surgery and Director of the Pediatric Surgical Oncology Program. Dr. Rhee’s areas of clinical expertise include pediatric surgical oncology as well as neonatal and general pediatric surgery. Dr. Rhee received his undergraduate degree from the University of Michigan and earned his medical degree from The Ohio State University College of Medicine. He completed his residency in general surgery at St. Joseph Mercy Hospital before completing fellowships at Johns Hopkins Hospital in Pediatric Surgery and Memorial Sloan Kettering Cancer Center in Pediatric Surgical Oncology. Dr. Rhee is a member of several professional societies, including the American College of Surgeons, American Pediatric Surgical Association, the Association of Academic Surgeons, the Children’s Oncology Group, and The International Society of Paediatric Surgical Oncology. Dr. Rhee’s research interests involve childhood tumors including neuroblastoma, sarcoma, Wilms tumor, hepatoblastoma, pancreatoblastoma, reconstruction for chest wall tumors, germ cell tumors, and desmoplastic small round cell tumors. His research interests also include use of 3D printing for simulation for surgical training, improving surgical outcomes in pediatric surgery and improving access to surgical care in low and middle-income countries. Dr. Rhee is rated as an Advanced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Appendicitis, Tracheoesophageal Fistula, Appendectomy, and Pancreaticoduodenectomy.

As instructor of oncology and pediatrics, Llosa’s research focus is the immunotherapy of sarcomas. My research focuses on understanding how the immune system interacts with cancer cells from sarcoma tumors. Sarcoma is a type of cancer that can occur in various locations in the body. Sarcoma is the general term for a broad group of cancers that includes tumors that form in the bones and in the soft (also called connective) tissues. Sarcomas affect people of all ages and some, such as Rhabdomyosarcoma, Neuroblastoma, Ewings sarcoma and Osteosarcoma, are more common in children and young adults. Treatments for sarcoma vary depending on tumor type, location and other factors. I concentrate in the immunotherapy of sarcomas. Immunotherapy (also called biologic therapy or biotherapy) is a type of cancer treatment designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. Immunotherapy works by stopping or slowing the growth of cancer cells, stopping cancer from spreading to other parts of the body, or helping the immune system increase its effectiveness at eliminating cancer cells. There are several types of immunotherapy, including monoclonal antibodies, non-specific immunotherapies, and cancer vaccines. My specific area of interest is the use of drugs that target immune system checkpoints. The immune system has checkpoints to keep itself from attacking other normal cells in the body. Cancer cells sometimes take advantage of these checkpoints to avoid being attacked by the immune system. CTLA-4 and PD-1/PD-L1 are checkpoint molecules found on immune system cells (T cells) that can be blocked with drugs leading to a general raise in the immune system of the patients which helps it attack cancer cells. These types of drugs are currently being given to patients with melanoma (skin cancer), lung cancer and kidney cancer with great success and they have been found to shrink advanced tumors in many people. The best part of the treatment is that many of these tumor responses have been long-lasting so far, and the side effects are generally less serious than when using chemotherapy. Larger clinical trials are now studying both drugs, both alone and/or in combination with other treatments. My task is and will continue to be using the same type of approach for attacking sarcomas and hopefully obtained the very promising results and long lasting responses observed with the use of immune checkpoint inhibitors in other types of cancer. Dr. Llosa is rated as an Advanced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Malignant Peripheral Nerve Sheath Tumor, Ewing Sarcoma, and Bone Marrow Transplant.

I am medical oncologist dedicated to the care of patients with genitourinary malignancies. My clinical and research focus is on the management of renal cell carcinoma (RCC). I have completed Medical Oncology Higher Specialist Training with Royal College of Physicians in Ireland and subsequently completed Advanced Medical Oncology Fellowship at the Memorial Sloan Kettering Cancer Center in New York. Dr. Ged is rated as an Advanced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, Nephrectomy, and Thrombectomy.

Dr. Ana Kiess's clinical focus is on the treatment of prostate cancer and head and neck cancers with external beam radiotherapy and radiopharmaceutical therapies. Her research concentrates on the integration of new radiopharmaceutical therapies and dosimetry techniques into the clinic. Dr. Kiess received her bachelors of science degree in chemical engineering from the University of Virginia, after which she obtained a doctorate of medicine and a doctorate of philosophy degree in biomedical engineering from Duke University. Following medical school, she matriculated to the resident staff at Memorial Sloan Kettering Cancer Center, receiving extensive oncologic training and research experience. She also completed a postdoctoral research fellowship at Johns Hopkins University in the Department of Radiology. Make A Gift. Dr. Kiess is rated as an Advanced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. Her top areas of expertise are Prostate Cancer, Laryngeal Cancer, Throat Cancer, Gastrostomy, and Adenoidectomy.